Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Botulinum Toxin Type A and Methylprednisolone in Treatment of Piriformis Syndrome
IRCT20191213045717N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of botulinum toxin type A and methylprednisolone in Piriformis syndrome (2 arms), sponsored by Iran University of Medical Sciences. Started Feb 2020; status: completed.
02
Drugs
botulinum toxin type Amethylprednisolone
03
Conditions
Piriformis syndrome
Beyond the preview
Go deeper on IRCT20191213045717N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191213045717N1.